Abstract
The clinical utility and ultimately guideline recommendations for aldosterone receptor-blocking agents in cardiovascular disorders is clearly mentioned by a number of major clinical outcome trials. This article reviews the pharmacology, clinical efficacy and safety of the two currently available receptor blocking agents: spironolactone and eplerenone. The potential utility of eplerenone and other mineralocorticoid receptor agents beyond current clinical indications will also be examined.
MeSH terms
-
Aldosterone / metabolism
-
Animals
-
Cardiovascular Agents / adverse effects
-
Cardiovascular Agents / pharmacology
-
Cardiovascular Agents / therapeutic use*
-
Cardiovascular Diseases / drug therapy*
-
Cardiovascular Diseases / metabolism
-
Eplerenone
-
Humans
-
Hydrocortisone / antagonists & inhibitors
-
Hydrocortisone / metabolism
-
Mineralocorticoid Receptor Antagonists / adverse effects
-
Mineralocorticoid Receptor Antagonists / pharmacology
-
Mineralocorticoid Receptor Antagonists / therapeutic use*
-
Receptors, Mineralocorticoid / metabolism
-
Spironolactone / adverse effects
-
Spironolactone / analogs & derivatives*
-
Spironolactone / pharmacology
-
Spironolactone / therapeutic use
Substances
-
Cardiovascular Agents
-
Mineralocorticoid Receptor Antagonists
-
Receptors, Mineralocorticoid
-
Spironolactone
-
Aldosterone
-
Eplerenone
-
Hydrocortisone